AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 6.35 |
|---|---|
| Change | -0.410 6.457% |
| 52 W H/L (in USD) | 5.228/2.240 |
| EBITDA (in USD) | -112.976M |
| PE Ratio | -- |
| Volume | 5103790 |
| Diluted Eps TTM | -0.84 |
| Total Assets (in USD) | 216.297M |
|---|---|
| Total Liabilities (in USD) | 26.848M |
| Revenue TTM (in USD) | 2.8M |
| Cash (in USD) | 20.025M |
| Market Cap (in USD) | 604.434 M |
| Revenue Per Share TTM | 0.020 |
| Gross Profit TTM (in USD) | -77.918M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683
360 949 1041
Employees: 140
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Sean McClain | Founder, CEO, Pres & Director | 1991 |
| 2. | Dr. Sarah Korman J.D., Ph.D. | Chief Legal Officer & Corp. Sec. | 1979 |
| 3. | Mr. Gregory T. Schiffman CPA, CPA, MBA | Chief Financial Officer | 1957 |
| 4. | Todd Bedrick CPA | Sr. VP & Chief Accounting Officer | NA |
| 5. | Mr. Jack Gold | Chief Marketing Officer | NA |
| 6. | Melissa Patterson Ph.D. | Chief of Staff | NA |
| 7. | Ms. Denise Dettore | Chief People Officer | NA |
| 8. | Dr. Andreas Busch Ph.D. | Chief Innovation Officer | 1963 |
| 9. | Jonathan Eads M.S. | Sr. VP of Informatics | NA |
| 10. | Thomas Wrona J.D., Ph.D. | Sr. VP of Intellectual Property | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -115.114M | -103.036M | -110.466M | -105.365M | -109.859M |
| Minority Interest | - | - | - | - | - |
| Net Income | -115.183M | -103.106M | -110.566M | -104.904M | -100.96M |
| Selling General Administrative | 35.058M | 36.174M | 36.257M | 40.552M | 28.78M |
| Gross Profit | -8.942M | -57.925M | -41.849M | 5.747M | 4.782M |
| Reconciled Depreciation | 11.742M | 13.389M | 14.101M | 13.037M | 6.654M |
| Ebit | -124.718M | -107.488M | -93.68M | -106.75M | -75.238M |
| Ebitda | -112.976M | -94.099M | -79.681M | -91.356M | -99.773M |
| Depreciation And Amortization | 11.742M | 13.389M | 13.999M | 15.394M | -24.535M |
| Operating Income | -124.718M | -108.888M | -115.515M | -106.75M | -75.238M |
| Other Operating Expenses | 127.518M | 113.422M | 121.233M | 112.497M | 80.02M |
| Interest Expense | 0.209M | 0.565M | 1.01M | 0.972M | 3.432M |
| Tax Provision | 0.069M | 0.07M | -0.448M | -0.461M | -8.899M |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -0.209M | -0.565M | -1.093M | -0.972M | -3.432M |
| Income Tax Expense | 0.069M | 0.07M | 0.1M | -0.461M | -8.899M |
| Total Revenue | 2.8M | 4.534M | 5.718M | 5.747M | 4.782M |
| Total Operating Expenses | 115.776M | 50.963M | 73.666M | 112.497M | 80.02M |
| Cost Of Revenue | 11.742M | 62.459M | 47.567M | - | 6.654M |
| Total Other Income Expense Net | 9.604M | 5.852M | 5.049M | 1.385M | -34.621M |
| Net Income From Continuing Ops | -115.183M | -103.106M | -106.492M | -104.904M | -100.96M |
| Net Income Applicable To Common Shares | - | - | - | -104.904M | -103.244M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 216.297M | 213.608M | 234.48M | 321.008M | 426.195M |
| Intangible Assets | 41.514M | 44.883M | 48.253M | 51.622M | 54.992M |
| Other Current Assets | 5.281M | 21.406M | 4.537M | 5.859M | 8.572M |
| Total Liab | 26.848M | 34.475M | 58.304M | 46.594M | 60.088M |
| Total Stockholder Equity | 189.449M | 179.133M | 176.176M | 274.414M | 366.107M |
| Other Current Liab | 16.592M | 19.592M | 19.303M | 20.481M | 17.434M |
| Common Stock | 0.015M | 0.012M | 0.009M | 0.009M | 0.009M |
| Capital Stock | 0.015M | 0.012M | 0.009M | 0.009M | 0.009M |
| Retained Earnings | -624.784M | -509.601M | -406.495M | -295.929M | -191.025M |
| Good Will | - | - | 0M | 21.335M | 21.335M |
| Other Assets | - | - | 0M | 3.146M | 18.137M |
| Cash | 20.025M | 41.213M | 88.555M | 59.955M | 252.569M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 22.765M | 28.656M | 29.558M | 30.27M | 33.859M |
| Current Deferred Revenue | 0.739M | 1.116M | 3.174M | 0.445M | 1.353M |
| Net Debt | -14.723M | -31.108M | -72.598M | -36.972M | -232.558M |
| Short Term Debt | 2.678M | 4.419M | 5.578M | 6.932M | 6.687M |
| Short Long Term Debt | 0.873M | 2.733M | 3.258M | 2.946M | 2.4M |
| Short Long Term Debt Total | 5.302M | 10.105M | 15.957M | 22.983M | 20.011M |
| Other Stockholder Equity | 813.627M | 688.726M | 582.699M | 570.454M | 130.941M |
| Property Plant Equipment | - | - | - | 58.042M | 58.652M |
| Total Current Assets | 149.573M | 133.831M | 120.578M | 186.863M | 273.079M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 124.267M | 71.212M | 25.297M | 104.476M | - |
| Net Receivables | - | 0M | 2.189M | 1.55M | 1.425M |
| Long Term Debt | - | 1.257M | 4.66M | 7.984M | 1.124M |
| Inventory | - | - | - | 15.023M | 10.513M |
| Accounts Payable | 2.756M | 3.529M | 1.503M | 2.412M | 8.385M |
| Accumulated Other Comprehensive Income | 0.591M | -0.004M | -0.037M | -0.12M | -0.013M |
| Non Currrent Assets Other | 1.436M | 1.759M | 1.537M | 3.146M | 18.137M |
| Non Current Assets Total | 66.724M | 79.777M | 113.902M | 134.145M | 153.116M |
| Capital Lease Obligations | 4.429M | 6.115M | 8.039M | 12.053M | 16.487M |
| Long Term Debt Total | - | - | - | - | 1.124M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | -50.365M | -41.577M | 32.807M | -126.982M | -1.2M |
| Total Cashflows From Investing Activities | -50.16M | -41.577M | 81.944M | -126.982M | -67.377M |
| Total Cash From Financing Activities | 105.949M | 82.526M | -4.483M | 5.237M | 336.193M |
| Net Income | -115.183M | -103.106M | -110.566M | -104.904M | -100.96M |
| Change In Cash | -37.136M | -31.453M | 12.825M | -203.084M | 208.218M |
| Begin Period Cash Flow | 58.214M | 89.667M | 76.842M | 279.926M | 71.708M |
| End Period Cash Flow | 21.078M | 58.214M | 89.667M | 76.842M | 279.926M |
| Total Cash From Operating Activities | -92.925M | -72.402M | -64.636M | -81.339M | -60.598M |
| Depreciation | 11.742M | 13.389M | 13.999M | 13.037M | 6.654M |
| Other Cashflows From Investing Activities | - | 0.939M | 0.254M | 0.65M | -29.33M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - | 210.396M |
| Other Cashflows From Financing Activities | - | - | 81.944M | 12.031M | 129.944M |
| Capital Expenditures | 1.107M | 0.404M | 0.86M | 16.175M | 38.047M |
| Change In Working Capital | 0.423M | -0.368M | 1.517M | -1.54M | -3.146M |
| Other Non Cash Items | -8.228M | -1.769M | 19.05M | 0.033M | 35.147M |
| Free Cash Flow | -94.032M | -72.806M | -65.496M | -97.514M | -98.645M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Company Fund | 3 months ago | 6910182 |
| 2. | ARK Genomic Revolution ETF | 2 months ago | 11316162 |
| 3. | ARK Genomic Revolution | 2 months ago | 11201282 |
| 4. | Fidelity Growth Compy Commingled Pl S | 3 months ago | 9928648 |
| 5. | State Street® SPDR® S&P® Biotech ETF | 2 months ago | 4658729 |
| 6. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 4253585 |
| 7. | iShares Russell 2000 ETF | 2 months ago | 3299915 |
| 8. | Columbia Acorn Inst | 3 months ago | 2566842 |
| 9. | Fidelity Growth Company K6 | 3 months ago | 2233380 |
| 10. | Fidelity Series Growth Company | 3 months ago | 1903033 |
| 11. | Fidelity Select Biotechnology | 3 months ago | 1540796 |
| 12. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 1490088 |
| 13. | US Small-Cap Growth II Equity Comp | 5 months ago | 1347300 |
| 14. | Fidelity Small Cap Index | 4 months ago | 1324709 |
| 15. | MFS New Discovery I | 3 months ago | 1263891 |
| 16. | ARK Venture D | 4 months ago | 1116800 |
| 17. | iShares Biotechnology ETF | 2 months ago | 977116 |
| 18. | Fidelity Extended Market Index | 3 months ago | 874661 |
| 19. | iShares Russell 2000 Growth ETF | 2 months ago | 864797 |
| 20. | Russell 2000 Equity Index Fund B | 5 months ago | 850969 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 5 months ago | 22382002 |
| 2. | ARK Investment Management LLC | 5 months ago | 12550799 |
| 3. | BlackRock Inc | 8 months ago | 10582975 |
| 4. | Redmile Group, LLC | 5 months ago | 8253316 |
| 5. | Vanguard Group Inc | 5 months ago | 7910205 |
| 6. | Geode Capital Management, LLC | 5 months ago | 3239623 |
| 7. | Ameriprise Financial Inc | 8 months ago | 3191011 |
| 8. | Schonfeld Strategic Advisors LLC | 5 months ago | 2349725 |
| 9. | Woodline Partners LP | 5 months ago | 2280783 |
| 10. | Baker Bros Advisors LP | 5 months ago | 2134803 |
| 11. | State Street Corp | 8 months ago | 2064951 |
| 12. | UBS Group AG | 8 months ago | 1993109 |
| 13. | Citadel Advisors Llc | 5 months ago | 1943636 |
| 14. | Massachusetts Financial Services Company | 5 months ago | 1719849 |
| 15. | Sumitomo Mitsui Trust Group Inc | 8 months ago | 1494047 |
| 16. | Parkman Healthcare Partners LLC | 5 months ago | 1458652 |
| 17. | Amova Asset Management Americas, Inc | 5 months ago | 1424778 |
| 18. | Two Sigma Investments LLC | 5 months ago | 1418416 |
| 19. | Fred Alger Management, LLC | 5 months ago | 1206800 |
| 20. | Charles Schwab Investment Management Inc | 5 months ago | 1115373 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...